A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease.

@article{Karaman2005A1S,
  title={A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease.},
  author={Yahya Karaman and F{\"u}sun Ferda Erdoğan and Emel K{\"o}seoğlu and Tayfun Turan and Ali Ozdemir Ersoy},
  journal={Dementia and geriatric cognitive disorders},
  year={2005},
  volume={19 1},
  pages={51-6}
}
The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713), in patients with advanced moderate Alzheimer's disease (AD) was evaluated in a 12-month placebo-controlled study. We aimed to investigate whether there was any evidence for the benefits of rivastigmine in patients with severe disease. These patients were compared with matched controls. In this study, 24 patients with advanced moderate AD received rivastigmine for 12 months. Another 20 patients received… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 43 references

Dose response effect of rivastigmine in the treatment of Alzheimer’s disease

  • R Anand, J Messina, R Hartman
  • Int J Geriatr Psychopharmacol
  • 2002

Similar Papers

Loading similar papers…